Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients

Table 1

Lipid-lowering medications in the 9950 coronary artery disease patients.

Lipid-lowering medications	Patients
Total number of patients	9950
Statin monotherapy	5885 (59%)
High potency	1692 (17%)
Moderate potency	2398 (24%)
Low potency	1795 (18%)
Combination 𝑡ℎ𝑒𝑟𝑎𝑝𝑦^∗	2730 (27%)
Statin plus ezetimibe	1378 (14%)
Statin plus niacin	866 (9%)
Statin plus fibrate	650 (7%)
Statin plus fish oil	69 (<1%)
Statin plus bile acid sequestrant	43 (<1%)
No statin	1335 (13%)
No statin but other lipid lowering 𝑡ℎ𝑒𝑟𝑎𝑝𝑦^†	389 (4%)
Ezetimibe	179 (2%)
Niacin	113 (1%)
Fibrate	170 (2%)
Fish oil	11 (<1%)
Bile acid sequestrant	37 (<1%)
No lipid-lowering therapy	946 (10%)

^*Among patients on a statin plus another lipid-lowering medication, 276 patients were on more than one non-statin lipid-lowering drug.
^†Among patients on no statin but another lipid-lowering medication, 121 patients were on more than one non-statin lipid-lowering drug.